Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

4D Pharma posts "exciting" development results from MicroRx

Tue, 16th Jun 2015 08:33
Pharmaceutical company 4D Pharma said it had made significant progress in its research efforts using its proprietary platform MicroRx.The Manchester-based outfit was able to identify candidates for the treatment of severe asthma, allergic asthma and rheumatoid arthritis.The group also identified bacteria that have "therapeutically relevant" effects in an industry standard model of multiple sclerosis.Furthermore, its pre-clinical work showed "clear efficacy" in preventing the development of multiple sclerosis.Chief scientific officer Alex Stevenson said: "These results are an exciting development in the progress of live biotherapeutics."To potentially treat a disease such as multiple sclerosis with an oral capsule of therapeutically functional bacteria would be a huge step forward in the treatment of this disease."Shares were up 3.76% to 897.5p on Tuesday at 08:32.

Related News

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM
15 Feb 2023

IN BRIEF: 4D Pharma shares cancelled from trading on London's AIM

4D Pharma PLC - Leeds-based pharmaceutical firm - Notes cancellation of its shares on AIM from Thursday, after it entered into administration in June ...

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil
3 Feb 2023

TRADING UPDATES: GCP Infra hails NAV rise; Jadestone profits from oil

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

DDDD.L News

AIM WINNERS & LOSERS: Quiz shares in style as sales top expectations
1 Apr 2022

AIM WINNERS & LOSERS: Quiz shares in style as sales top expectations

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

IN BRIEF: 4D Pharma annual pretax loss widens, sees itself well-funded
1 Apr 2022

IN BRIEF: 4D Pharma annual pretax loss widens, sees itself well-funded

4D Pharma PLC - Leeds, England-based pharmaceutical company - Posts widened pretax loss for 2021. Pretax loss stretches to GBP57.5 million from GBP30....

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings
23 Mar 2022

AIM WINNERS & LOSERS: RWS and James Cropper sink on profit warnings

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

4d Pharma shares jump on positive results from cancer treatment study
23 Mar 2022

4d Pharma shares jump on positive results from cancer treatment study

(Alliance News) - 4d Pharma PLC shares soared on Wednesday after the company said that its phase I/II study for the combination of MRx0518 and Keytrud...

IN BRIEF: 4D Pharma registers for potential ADS offering in US
9 Mar 2022

IN BRIEF: 4D Pharma registers for potential ADS offering in US

4D Pharma PLC - Leeds, England-based pharmaceutical company - Files shelf registration statement to the US Securities & Exchange Commission following ...

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit
22 Feb 2022

TRADING UPDATES: Angling Direct ups revenue; Ceiba takes Omicron hit

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

4d Pharma gets FDA clearance for potential Parkinson's treatments
22 Feb 2022

4d Pharma gets FDA clearance for potential Parkinson's treatments

(Sharecast News) - Biotherapeutic pharmaceutical company 4D Pharma announced on Tuesday that the United States Food and Drug Administration (FDA) has ...

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial
27 Jan 2022

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial

IN BRIEF: 4D Pharma sees encouraging results for MRx-4DP0004 in trial